DUBLIN, Eire, and Boston MA, July 28, 2021, Amryt (Nasdaq: AMYT, Aim: AMYT), a world, commercial-stage biopharmaceutical business devoted to attaining, acquiring and commercializing novel treatment options for exceptional disorders, is delighted to announce that all resolutions introduced to shareholders at both equally of today’s Standard Meetings ended up duly passed.
Accordingly, at the Basic Assembly held in relation to the Company’s proposed acquisition of Chiasma, Inc., Amryt Shareholders permitted the resolutions essential to give the Amryt Administrators the requisite authorities to problem and allot the New Regular Shares in purchase to effect the Transaction. The Chiasma Special Conference, at which Chiasma Shareholders will consider and vote on the Transaction, will just take area at 9.am. Japanese Time on August 3, 2021 and if accredited, Closing of the Transaction and the difficulty of the New Standard Shares will acquire position shortly thereafter.
The entire textual content of each individual resolution was included in the discover of the meeting, which was posted to shareholders on June 28, 2021, and is obtainable on the Company’s website www.amrytpharma.com. Capitalised terms not usually defined in this announcement have the meanings presented to them in the Company’s round and recognize of typical assembly dated June 28, 2021.
About Amryt
Amryt is a global commercial-stage biopharmaceutical firm focused on attaining, creating and commercializing innovative treatments to assistance make improvements to the lives of individuals with scarce and orphan conditions. Amryt includes a sturdy and rising portfolio of business and enhancement belongings.
Amryt’s business business enterprise comprises two orphan disorder products – metreleptin (Myalept®/ Myalepta®) and lomitapide (Juxtapid®/ Lojuxta®).
Myalept®/Myalepta® (metreleptin) is accepted in the US (beneath the trade name Myalept®) as an adjunct to eating plan as substitute therapy to treat the difficulties of leptin deficiency in individuals with congenital or acquired generalized lipodystrophy (GL) and in the EU (beneath the trade name Myalepta®) as an adjunct to food plan for the treatment of leptin deficiency in individuals with congenital or acquired GL in adults and kids two decades of age and earlier mentioned and familial or obtained partial lipodystrophy (PL) in older people and small children 12 several years of age and earlier mentioned for whom typical remedies have unsuccessful to reach sufficient metabolic control. For additional information and facts, be sure to observe this backlink.
Juxtapid®/Lojuxta® (lomitapide) is approved as an adjunct to a small-fats eating plan and other lipid-reducing medicinal products for older people with the rare cholesterol ailment, Homozygous Familial Hypercholesterolaemia (“HoFH”) in the US, Canada, Colombia, Argentina and Japan (underneath the trade title Juxtapid®) and in the EU, Israel and Brazil (under the trade identify Lojuxta®). For further data, please adhere to this website link.
Amryt’s guide enhancement applicant, Oleogel-S10 (Filsuvez®) is a possible treatment for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (“EB”), a uncommon and distressing genetic skin disorder impacting younger youngsters and grown ups for which there is at present no permitted remedy. Filsuvez® has been chosen as the manufacturer title for Oleogel-S10. The merchandise does not currently have regulatory approval to treat EB. In June 2021, Amryt gained affirmation from the Fda that its NDA for Oleogel-S10 had been approved and granted precedence overview.
Amryt’s pre-medical gene treatment system, AP103, offers a possible therapy for patients with Dystrophic EB, and is also probably applicable to other genetic diseases.
For additional information on Amryt, such as products and solutions, be sure to visit www.amrytpharma.com.
The individual earning this notification on behalf of Amryt is Rory Nealon, CFO/COO and Organization Secretary.
Financial Advisors
Shore Funds (Edward Mansfield, Daniel Bush, John Extra) are NOMAD and Joint Broker to Amryt in the British isles. Stifel (Ben Maddison) are Joint Broker to the firm in the United kingdom.
Forward-Hunting Statements
This conversation relates to a proposed business mix transaction between Amryt and Chiasma. This conversation involves ahead-on the lookout statements in the which means of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Trade Act of 1934. Ahead-seeking statements relate to upcoming events and anticipated success of functions, business enterprise techniques, the expected added benefits of the proposed transaction, the predicted effect of the proposed transaction on the combined company’s business and future monetary and working benefits, the predicted sum and timing of synergies from the proposed transaction, the expected closing day for the proposed transaction and other facets of our operations or operating success. These ahead-looking statements usually can be recognized by phrases these kinds of as “will,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other terms or phrases of similar import. It is uncertain whether any of the activities expected by the forward-wanting statements will transpire or happen, or if any of them do, what impact they will have on the benefits of functions and economical affliction of the put together providers or the rate of Amryt or Chiasma inventory. These forward-seeking statements require specified pitfalls and uncertainties, lots of of which are over and above the parties’ manage, that could result in true results to vary materially from those people indicated in these types of ahead-wanting statements, which includes but not constrained to: the impression of general public health crises, this sort of as pandemics (including coronavirus (COVID-19)) and epidemics and any associated firm or authorities insurance policies and actions to safeguard the health and protection of folks or government policies or actions to sustain the operating of nationwide or world economies and marketplaces the effect of the announcement of the merger on the means of Amryt or Chiasma to keep and hire critical personnel and manage interactions with shoppers, suppliers and other individuals with whom Amryt or Chiasma do enterprise, or on Amryt’s or Chiasma’s running results and small business frequently threats that the merger disrupts present options and operations and the potential difficulties in worker retention as a consequence of the merger the end result of any legal proceedings similar to the merger the skill of the functions to consummate the proposed transaction on a well timed foundation or at all the fulfillment of the ailments precedent to consummation of the proposed transaction, such as the capability of Amryt to effectively combine Chiasma’s functions the means of Amryt to employ its ideas, forecasts and other expectations with respect to Amryt’s business just after the completion of the transaction and realize envisioned synergies and organization disruption adhering to the merger. These hazards, as very well as other risks linked to the proposed transaction, are included in the registration statement on Variety F-4, and if needed, the registration assertion on Sort F-6, and have been bundled in the Definitive Proxy Statement/prospectus that was submitted with the SEC on July 2, 2021 in connection with the proposed transaction. When the record of things presented here is, and the listing of variables to be presented in the registration statement on Variety F-4, and if necessary, the registration assertion on Type F-6, are, regarded consultant, no these list must be regarded as to be a entire assertion of all probable hazards and uncertainties. For further details about other aspects that could lead to precise effects to vary materially from people explained in the ahead-searching statements, see the segment entitled “Risk Factors” and “Management’s Discussion and Examination of Fiscal Condition and Final results of Operations” in Amryt’s Once-a-year Report on Form 20-F for the 12 months ended December 31, 2020 submitted with the SEC on April 30, 2021 and Amryt’s Variety 6-K for the quarter ended March 31, 2021 filed with the SEC on May 4, 2021, and Chiasma’s most recent Quarterly Experiences on Form 10-Q and Annual Report on Kind 10-K. The forward-searching statements incorporated in this interaction are built only as of the day hereof. Neither Amryt nor Chiasma undertakes any obligation to update any forward-seeking statements to replicate subsequent gatherings or circumstances, apart from as expected by legislation.
No Provide or Solicitation
This conversation is not supposed to and shall not represent an provide to get or sell or the solicitation of an offer to acquire or offer any securities, or a solicitation of any vote or acceptance, nor shall there be any sale of securities in any jurisdiction in which this sort of supply, solicitation or sale would be illegal prior to registration or qualification underneath the securities legal guidelines of any these jurisdiction. No supplying of securities shall be created, other than by suggests of a prospectus conference the specifications of Section 10 of the U.S. Securities Act of 1933, as amended.
Extra Details about the Merger and Where to Find It
In connection with the proposed transaction, on June 15, 2021, Amryt filed with the SEC a registration assertion on Form F-4, which was declared productive by the SEC on July 1, 2021, that contains a proxy assertion of Chiasma and that also constitutes a prospectus of Amryt, and just about every of Chiasma and Amryt might file with the SEC other files concerning the proposed transaction. This communication is not a substitute for the Definitive Proxy Assertion/prospectus or registration assertion or any other document that Amryt or Chiasma may file with the SEC. The Definitive Proxy Statement/prospectus was mailed to stockholders of Amryt and Chiasma on or about July 2, 2021. Buyers AND Security HOLDERS ARE URGED TO Examine THE REGISTRATION Statement ON Kind F-4 AND THE DEFINITIVE PROXY Assertion/PROSPECTUS, AS Very well AS ANY AMENDMENTS OR Dietary supplements TO Those people Documents AND ANY OTHER Pertinent Paperwork TO BE Filed WITH THE SEC IN Relationship WITH THE PROPOSED TRANSACTION, IF AND WHEN THEY Turn into Obtainable, Simply because THEY Consist of OR WILL Have Critical Information and facts ABOUT AMRYT, CHIASMA AND THE PROPOSED TRANSACTION. Investors and safety holders might attain copies of these paperwork, once such documents are submitted with the SEC, totally free of demand by way of the web site maintained by the SEC at www.sec.gov or from Amryt at its internet site, https://amrytpharma.com, or from Chiasma at its web-site, https://chiasma.com. Documents submitted with the SEC by Amryt will be offered absolutely free of charge by accessing Amryt’s web-site less than the heading Investors, or, alternatively, by getting in contact with Amryt’s Trader Relations section at ir@amrytpharma.com, and files filed with the SEC by Chiasma will be offered no cost of demand by accessing Chiasma’s internet site at https://chiasma.com less than the heading Information and Investors or, alternatively, by calling Chiasma’s Investor Relations department at investor.relations@chiasmapharma.com.
Contributors in the Solicitation
Amryt and Chiasma and sure of their respective directors and government officers and other users of management and staff may possibly be considered to be members in the solicitation of proxies from the stockholders of Chiasma in regard of the proposed transaction less than the rules of the SEC. Information about Chiasma’s directors and executive officers is readily available in Chiasma’s definitive proxy statement dated April 26, 2021 for its 2021 Yearly Assembly of Stockholders. Facts about Amryt’s directors and executive officers is out there in Amryt’s Annual Report on Form 20-F filed with the SEC on April 30, 2021. Other information and facts pertaining to the participants in the proxy solicitation and a description of their immediate and oblique interests, by stability holdings or if not, will be contained in the Definitive Proxy Assertion/prospectus, which was submitted on July 2, 2021, and other related resources to be filed with the SEC regarding the proposed transaction when they turn out to be obtainable. Investors ought to browse the proxy assertion/prospectus very carefully when it will become offered prior to generating any voting or investment decision conclusions. You may acquire free copies of these files from Chiasma or Amryt working with the resources indicated earlier mentioned.
Contacts
Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200, ir@amrytpharma.com
Edward Mansfield, Shore Money, NOMAD, +44 () 207 468 7906, edward.mansfield@shorecap.co.united kingdom
Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564, tim@lifesciadvisors.com
Amber Fennell, Consilium Strategic Communications, +44 () 203 709 5700, fennell@consilium-comms.com
